Inovio Pharmaceuticals (INO) Change in Cash (2010 - 2026)

Inovio Pharmaceuticals has reported Change in Cash for 17 years, with the latest figure at -$18.0 million in Q1 2026.

• Quarterly Change in Cash rose 30.49% year-over-year to -$18.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$13.6 million (down 167.17% YoY) and the FY2025 annual result came in at -$21.5 million, down 141.82% from the prior year.
• Change in Cash slipped to -$18.0 million in Q1 2026 per INO's latest filing, from $7.7 million in the prior quarter.
• Over five years, Change in Cash peaked at $44.1 million in Q4 2024 and troughed at -$33.9 million in Q3 2023.
• A 5-year average of -$2.6 million and a median of -$12.1 million in 2022 frame the typical range for Change in Cash.
• The sharpest annual moves came in 2024 and 2025: Change in Cash soared 1081.94% in 2024, then sank 589.47% in 2025.
• Over 5 years, Change in Cash stood at $24.3 million in 2022, then sank by 118.46% to -$4.5 million in 2023, then jumped by 1081.94% to $44.1 million in 2024, then plunged by 82.54% to $7.7 million in 2025, then slumped by 333.61% to -$18.0 million in 2026.
• According to Business Quant data, Change in Cash over the past three periods registered -$18.0 million, $7.7 million, and $12.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.